Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

New SonicOne® O.R. Data Being Presented at WUWHS 2016 Congress: Shows Effectiveness in Removing Biofilm

Misonix,Inc.
Posted on: 26 Sep 16

PR Newswire

FARMINGDALE, N.Y., Sept. 26, 2016

FARMINGDALE, N.Y., Sept. 26, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced new data demonstrating the effectiveness of the SonicOne O.R. ultrasonic debridement device in removing biofilm from potentially contaminated surfaces associated with metal knee and hip implants. The data will be presented during the World Union of Wound Healing Societies ('WUWHS") to be held September 25 - 29, 2016 in Florence, Italy.  

It is estimated that 90% of chronic wounds contain bacteria and fungi living within biofilm. The new data suggests SonicOne O.R. can play a role in addressing the significant problem biofilm plays in preventing chronic wounds from healing.

"The early data are very encouraging. The studies showed complete removal of biofilm from infected titanium plates. The plates simulated biofilm that grows on metal knee and hip implants. Biofilm formation and removal is a significant problem in infected implants," said Dr. Mark S. Granick, Professor and Chief, Division of Plastic Surgery, Rutgers New Jersey Medical School. Dr. Granick added, "While more studies are needed, SonicOne continues to demonstrate utility as an infection control platform during wound debridement."

Stavros Vizirgianakis, Interim Chief Executive Officer of Misonix, commented, "We are pleased that the SonicOne O.R. system is being recognized as a viable solution to a recurring problem that can profoundly impact the quality of life for the growing number of implant recipients throughout the world. It is gratifying that globally recognized experts like Dr. Granick are involved in this ongoing research. The SonicOne O.R. features unique attributes that can enhance healing in diabetic ulcers, wounds from burns and now, potentially, implant infections. We look forward to the forthcoming results of the ongoing research."

Misonix also announced a Live YouTube event from Florence, Italy featuring Dr. Granick's presentation during the World Union Wound Healing Society Meeting. The Live event can be viewed at https://www.youtube.com/embed/VZ3udLGk0e4 on Monday, September 26th at 5 pm EST.  The presentation is expected to cover the clinical benefits of the use of the newly launched SonicVac® addition to the SonicOne O.R. device.  The SonicVac, which was launched in April of this year, uniquely combines aspiration and ultrasound during wound debridement. This combination reduces spray during the procedure while capturing debris and bacteria from the wound.  

"We're particularly excited that Dr. Granick is hosting this event and we look forward to his live presentation at WUWHS 2016 for a worldwide audience.  Events like this are an important part of the Misonix education platform and will expose clinicians from around the world to our unique technologies," states Scott Ludecker, Senior Vice President, Global Sales and Marketing with Misonix.

The SonicOne O.R. System is an innovative ultrasonic surgical debridement system that allows surgeons to address the challenges chronic wounds present to them, the patient and the healthcare system. SonicOne O.R. establishes a new standard in surgical wound bed preparation, an essential first step in the wound healing process.  The new SonicOne procedure will be sold and distributed through the Misonix sales team in the United States and its domestic and international distribution networks.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.

Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

Corporate Contact


Misonix Contact:

 Investor Contact:                                           

Richard Zaremba

Joe Diaz                                              

631-694-9555

Lytham Partners            

invest@misonix.com

602-889-9700


info@misonix.com        

 

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, the completion of the investigation related to identified deficiencies in internal control over financial reporting, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Logo - http://photos.prnewswire.com/prnh/20160201/328020LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-sonicone-or-data-being-presented-at-wuwhs-2016-congress-shows-effectiveness-in-removing-biofilm-300333749.html

SOURCE Misonix, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 26/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.